Skip to main content

Table 3 The comparison of clinical parameters at baseline

From: Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?

 

RLDA (n = 27)

MHDA (n = 37)

p value

Age (years)

56.3 ± 15.7

59.9 ± 12.1

0.334

Female/male

18/9

31/6

0.110

Disease duration (years)

10.3 ± 8.3

15.1 ± 13.6

0.082

PSL dose (mg/day)

2.2 ± 2.5

1.8 ± 2.1

0.483

MTX dose (mg/week)

5.2 ± 3.4

6.1 ± 3.6

0.321

ESR (mm/h)

53.1 ± 33.9

68.9 ± 29.5

0.056

CRP (mg/dL)a

1.7 (0.4–3.1)

1.3 (0.6–2.9)

0.807

WBC (/μL)

7429.6 ± 2078.1

5886.5 ± 2150.2

0.005

% neutrophils

68.3 ± 9.2

69.0 ± 9.3

0.775

% eosinophils

2.0 ± 1.1

2.6 ± 2.8

0.418

% basophils

0.4 ± 0.2

0.4 ± 0.2

0.699

% monocytes

5.9 ± 1.6

4.9 ± 1.9

0.035

% lymphocytes

22.4 ± 7.9

22.0 ± 7.3

0.857

MMP-3 (ng/mL)a

158.0 (95.0–399.3)

134.5 (69.1–500.0)

0.579

ACPA (U/mL)a

61.4 (10.7–100.0)

99.1 (15.1–100.0)

0.393

ACPA ≥ 60 U/mL, n (%)

13 (50.0)

21 (58.3)

0.515

RF (U/mL)a

33 (10–100)

61.5 (23.8–211.8)

0.082

RF ≥ 40 U/mL, n (%)

12 (48.0)

22 (64.7)

0.199

DAS28-ESR

4.5 ± 1.4

5.3 ± 1.0

0.008

  1. The data are expressed as the mean ± standard deviation, with the exception of skewed variables (a), which are represented as medians (interquartile range)
  2. RLDA remission and low disease activity; MHDA moderate and high disease activity; PSL prednisolone; MTX methotrexate; ESR erythrocyte sedimentation rate; CRP C-reactive protein; WBC white blood cell count; MMP-3 matrix metalloproteinase-3; ACPA anti-cyclic citrullinated peptide antibody; RF rheumatoid factor; DAS28 Disease Activity Score in 28 joints